NCT07100106View on ClinicalTrials.gov

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions
Breast Cancer
Interventions
DRUG

GDC-4198

GDC-4198 will be administered orally.

DRUG

Giredestrant

Giredestrant will be administered orally.

DRUG

Abemaciclib

Abemaciclib will be administered orally.

Trial Locations (5)

5000

RECRUITING

Cancer Research SA, Adelaide

11772

RECRUITING

New York Cancer & Blood Specialists, East Patchogue

60099

RECRUITING

City of Hope® Cancer Center Chicago, Zion

91010

RECRUITING

City of Hope, Duarte

92618

RECRUITING

City of Hope - Orange County Lennar Foundation Cancer Center, Irvine

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Roche (China) Holding Ltd.

UNKNOWN

lead

Genentech, Inc.

INDUSTRY